Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma

Journal of Hepatology

Volumn 54, Issue 6, 2011, Pages 1237-1243

  Xu, Chun Fang ^a   Reck, Brian H ^b   Goodman, Vicki L ^e   Xue, Zhengyu ^b   Huang, Lingkang ^b   Barnes, Michael R ^f   Koshy, Beena ^b   Spraggs, Colin F ^a   Mooser, Vincent E ^c   Cardon, Lon R ^c   Pandite, Lini N ^d  

^a GLAXOSMITHKLINE   (United Kingdom)

^b Genetics Division   (United States)

^c Genetics Division   (United States)

^d Oncology Research and Development   (United States)

^e Oncology Research and Development   (United States)

^f NONE   (United Kingdom)

Author keywords

Alanine aminotransferase; GW786034; Hepatotoxicity; HFE; Pharmacogenetics

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; GLYCINE; HFE PROTEIN; PAZOPANIB; PLACEBO; THREONINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENE REPLICATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC VARIABILITY; GENOTYPE; HEMOCHROMATOSIS; HUMAN; HYPERTRANSAMINASEMIA; KIDNEY CARCINOMA; LIVER FAILURE; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; ALANINE TRANSAMINASE; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; FEMALE; GENES, MHC CLASS I; GENES, MHC CLASS II; GENETIC MARKERS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; KIDNEY NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PYRIMIDINES; SULFONAMIDES;

EID: 79956146844     PISSN: 01688278     EISSN: 01688278     Source Type: Journal    
DOI: 10.1016/j.jhep.2010.09.028     Document Type: Article

References (29)

1. G. Sonpavde, and T.E. Hutson Pazopanib: a novel multitargeted tyrosine kinase inhibitor Curr Oncol Rep 9 2007 115 119 (Pubitemid 46332383)
2. GlaxoSmithKline. Votrient™ (pazopanib) tablets prescribing information. Available from: < http://www.accessdata.fda.gov/drugsatfda-docs/ label/2009/022465lbl.pdf >.
3. European Medicines Agency. Votrient (pazopanib) authorisation details. Available from: < http://www.ema.europa.eu/ema/index.jsp?curl=pages/ medicines/human/medicines/001141/human-med-001337.jsp&murl=menus/medicines/ medicines.jsp&mid=WC0b01ac058001d124&jsenabled=true >.
4. N. Altorki, J. Heymach, M. Guarino, P. Lee, E. Felip, and T. Bauer Phase II study of pazopanib (GW786034) given preoperatively in stage I-II non-small cell lung cancer (NSCLC): a proof-of-concept study Ann Oncol 19 2008 viii89
5. M. Friedlander, K.C. Hancock, B. Benigno, D. Rischin, M. Messing, and C.A. Stringer Pazopanib (GW786034) is active in women with advanced Epithelial ovarian, fallopian tube, and peritoneal cancers: results of a phase II study Ann Oncol 19 2008 viii211
6. S. Sleijfer, I. Ray-Coquard, Z. Papai, A. Le Cesne, M. Scurr, and P. Schoffski Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043) J Clin Oncol 27 2009 3126 3132
7. S.K. Taylor, S. Chia, S. Dent, M. Clemons, P. Grenci, and L. Wang A phase II study of GW786034 (pazopanib) in patients with recurrent or metastatic invasive breast carcinoma: results after completion of stage I: a trial of the Princess Margaret Hospital Phase II Consortium J Clin Oncol 27 2009 [abstr 1133]
8. C.N. Sternberg, I.D. Davis, J. Mardiak, C. Szczylik, E. Lee, and J. Wagstaff Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 2010 1061 1068
9. T.E. Hutson, I.D. Davis, J.P. Machiels, P.L. De Souza, S. Rottey, and B.F. Hong Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma J Clin Oncol 28 2010 475 480
10. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Kidney Cancer. Available from: < http://www.nccn.org/ professionals/physician-gls/PDF/kidney.pdf >.
11. S.K. Sharma, A. Balamurugan, P.K. Saha, R.M. Pandey, and N.K. Mehra Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment Am J Respir Crit Care Med 166 2002 916 919 (Pubitemid 35193218)
12. K. Hirata, H. Takagi, M. Yamamoto, T. Matsumoto, T. Nishiya, and K. Mori Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study Pharmacogenomics J 8 2008 29 33
13. J. O'Donohue, K.A. Oien, P. Donaldson, J. Underhill, M. Clare, and R.N. MacSween Co-amoxiclav jaundice: clinical and histological features and HLA class II association Gut 47 2000 717 720
14. A. Kindmark, A. Jawaid, C.G. Harbron, B.J. Barratt, O.F. Bengtsson, and T.B. Andersson Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis Pharmacogenomics J 8 2008 186 195 (Pubitemid 351712643)
15. A.K. Daly, P.T. Donaldson, P. Bhatnagar, Y. Shen, I. Pe'er, and A. Floratos HLA-B5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin Nat Genet 41 2009 816 819
16. Wright TM. MHC II haplotype marker for lumiracoxib injury [presentation at AASLD/FDA/NIH/PhRMA Hepatotoxicity Special Interest Group Conference]. 2009. Available from: < http://www.aasld.org/conferences/educationtraining/ Documents/Hepatoxicity%20Slides/Wright.pdf >.
17. C.F. Xu, B.H. Reck, Z. Xue, L. Huang, K.L. Baker, and M. Chen Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism Br J Cancer 102 2010 1371 1377
18. J.B. Fan, A. Oliphant, R. Shen, B.G. Kermani, F. Garcia, and K.L. Gunderson Highly parallel SNP genotyping Cold Spring Harb Symp Quant Biol 68 2003 69 78 (Pubitemid 38955554)
19. J.D. Taylor, D. Briley, Q. Nguyen, K. Long, M.A. Iannone, and M.S. Li Flow cytometric platform for high-throughput single nucleotide polymorphism analysis Biotechniques 30 2001 661 666 [668-669]
20. K.J. Livak, J. Marmaro, and J.A. Todd Towards fully automated genome-wide polymorphism screening Nat Genet 9 1995 341 342
21. S.J. Chanock, T. Manolio, M. Boehnke, E. Boerwinkle, D.J. Hunter, and G. Thomas Replicating genotype-phenotype associations Nature 447 2007 655 660 (Pubitemid 46889722)
22. J.K. Olynyk, M.W. Knuiman, M.L. Divitini, H.C. Bartholomew, D.J. Cullen, and L.W. Powell Effects of HFE gene mutations and alcohol on iron status, liver biochemistry and morbidity J Gastroenterol Hepatol 20 2005 1435 1441 (Pubitemid 43960844)
23. J.E. Nelson, R. Bhattacharya, K.D. Lindor, N. Chalasani, S. Raaka, and E.J. Heathcote HFE C282Y mutations are associated with advanced hepatic fibrosis in Caucasians with nonalcoholic steatohepatitis Hepatology 46 2007 723 729 (Pubitemid 47436118)
24. H. Uto, J. Kurogi, Y. Takahama, K. Kusumoto, K. Hayashi, and A. Ido Alanine aminotransferase flare-up in hepatitis C virus carriers with persistently normal alanine aminotransferase levels in a hyperendemic area of Japan J Gastroenterol 42 2007 673 680 (Pubitemid 47278693)
25. A.L. Dixon, L. Liang, M.F. Moffatt, W. Chen, S. Heath, and K.C. Wong A genome-wide association study of global gene expression Nat Genet 39 2007 1202 1207 (Pubitemid 47482680)
26. F. Forooghian, and B. Das Anti-angiogenic effects of ribonucleic acid interference targeting vascular endothelial growth factor and hypoxia-inducible factor-1alpha Am J Ophthalmol 144 2007 761 768 (Pubitemid 47614953)
27. P.B. Watkins Idiosyncratic liver injury: challenges and approaches Toxicol Pathol 33 2005 1 5 (Pubitemid 40216797)
28. S. Verma, and N. Kaplowitz Diagnosis, management and prevention of drug-induced liver injury Gut 58 2009 1555 1564
29. R.J. Andrade, M. Robles, E. Ulzurrun, and M.I. Lucena Drug-induced liver injury: insights from genetic studies Pharmacogenomics 10 2009 1467 1487